WO2001074791A1 - Derives de diazepane ou sels desdits composes - Google Patents

Derives de diazepane ou sels desdits composes Download PDF

Info

Publication number
WO2001074791A1
WO2001074791A1 PCT/JP2001/002673 JP0102673W WO0174791A1 WO 2001074791 A1 WO2001074791 A1 WO 2001074791A1 JP 0102673 W JP0102673 W JP 0102673W WO 0174791 A1 WO0174791 A1 WO 0174791A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
salts
derivatives
blood
diazepan
Prior art date
Application number
PCT/JP2001/002673
Other languages
English (en)
French (fr)
Inventor
Fukushi Hirayama
Hiroyuki Koshio
Tsukasa Ishihara
Norio Seki
Shunichiro Hachiya
Keizo Sugasawa
Ryota Shiraki
Yuji Koga
Yuzo Matsumoto
Takeshi Shigenaga
Souichirou Kawazoe
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18611560&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2001074791(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharmaceutical Co., Ltd. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to US10/148,544 priority Critical patent/US6642224B1/en
Priority to AU2001244634A priority patent/AU2001244634A1/en
Priority to DE60103390T priority patent/DE60103390T2/de
Priority to EP01917634A priority patent/EP1273575B1/en
Priority to JP2001572486A priority patent/JP3788349B2/ja
Priority to CA002395846A priority patent/CA2395846C/en
Priority to AT01917634T priority patent/ATE267178T1/de
Publication of WO2001074791A1 publication Critical patent/WO2001074791A1/ja
Priority to US10/656,129 priority patent/US7307074B2/en
Priority to US12/203,640 priority patent/USRE43481E1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2001/002673 2000-03-31 2001-03-29 Derives de diazepane ou sels desdits composes WO2001074791A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/148,544 US6642224B1 (en) 2000-03-31 2001-03-29 Diazepan derivatives or salts thereof
AU2001244634A AU2001244634A1 (en) 2000-03-31 2001-03-29 Diazepane derivatives or salts thereof
DE60103390T DE60103390T2 (de) 2000-03-31 2001-03-29 Diazepinderivate oder deren salze
EP01917634A EP1273575B1 (en) 2000-03-31 2001-03-29 Diazepane derivatives or salts thereof
JP2001572486A JP3788349B2 (ja) 2000-03-31 2001-03-29 ジアゼパン誘導体又はその塩
CA002395846A CA2395846C (en) 2000-03-31 2001-03-29 Diazepan derivatives or salts thereof
AT01917634T ATE267178T1 (de) 2000-03-31 2001-03-29 Diazepinderivate oder deren salze
US10/656,129 US7307074B2 (en) 2000-03-31 2003-09-08 Diazepan derivatives or salts thereof
US12/203,640 USRE43481E1 (en) 2000-03-31 2008-09-03 Diazepan derivatives or salts thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000096858 2000-03-31
JP2000-096858 2000-03-31

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/148,544 A-371-Of-International US6642224B1 (en) 2000-03-31 2001-03-29 Diazepan derivatives or salts thereof
US10148544 A-371-Of-International 2001-03-29
US10/656,129 Division US7307074B2 (en) 2000-03-31 2003-09-08 Diazepan derivatives or salts thereof

Publications (1)

Publication Number Publication Date
WO2001074791A1 true WO2001074791A1 (fr) 2001-10-11

Family

ID=18611560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/002673 WO2001074791A1 (fr) 2000-03-31 2001-03-29 Derives de diazepane ou sels desdits composes

Country Status (21)

Country Link
US (3) US6642224B1 (ja)
EP (2) EP1273575B1 (ja)
JP (1) JP3788349B2 (ja)
KR (1) KR100739359B1 (ja)
CN (1) CN1226292C (ja)
AR (1) AR027985A1 (ja)
AT (2) ATE267178T1 (ja)
AU (2) AU776053B2 (ja)
BR (1) BR0101264A (ja)
CA (1) CA2395846C (ja)
DE (2) DE60103390T2 (ja)
DK (1) DK1273575T3 (ja)
ES (2) ES2217129T3 (ja)
HU (1) HUP0101333A3 (ja)
MX (1) MXPA01003279A (ja)
PL (1) PL207651B1 (ja)
PT (1) PT1273575E (ja)
RU (1) RU2257381C2 (ja)
TR (1) TR200401955T4 (ja)
TW (1) TW575569B (ja)
WO (1) WO2001074791A1 (ja)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064567A2 (en) * 2000-11-28 2002-08-22 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
WO2003050088A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
WO2003087057A1 (en) * 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
JP2006527708A (ja) * 2003-06-18 2006-12-07 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 血栓症の治療のための凝固因子ＸａおよびＶＩＩａの阻害剤としての１−［（４−エチニルフェニル）］−２−［（フェニル）］−ピロリジン−１，２−ジカルボキサミド誘導体
US7160878B2 (en) 2000-07-27 2007-01-09 Eli Lilly And Company Substituted heterocyclic amides
WO2007055183A1 (ja) * 2005-11-08 2007-05-18 Astellas Pharma Inc. ベンゼン誘導体又はその塩
US7390908B2 (en) 2001-08-17 2008-06-24 Astrazeneca Ab Compounds effecting glucokinase
WO2008123017A1 (ja) * 2007-03-09 2008-10-16 Daiichi Sankyo Company, Limited 新規なジアミド誘導体
WO2010005087A1 (ja) 2008-07-11 2010-01-14 味の素株式会社 アミジン誘導体
WO2010038689A1 (ja) * 2008-09-30 2010-04-08 アステラス製薬株式会社 経口投与用医薬組成物
US8207202B2 (en) 2005-10-19 2012-06-26 Astrazeneca Ab Benzamide compounds useful as histone deacetylase inhibitors
US8227506B2 (en) 2005-02-02 2012-07-24 Ajinomoto., Inc. Benzamidine compound
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259485B1 (en) * 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
PL204898B1 (pl) * 2000-11-22 2010-02-26 Astellas Pharma Inc Podstawiona pochodna benzenu i zawierająca ja kompozycja farmaceutyczna oraz jej zastosowanie
US7511066B2 (en) 2003-09-30 2009-03-31 Eli Lilly And Company Antithrombotic aromatic ethers
US7700628B2 (en) 2004-11-24 2010-04-20 Eli Lilly And Company Aromatic ether derivatives useful as thrombin inhibitors
EP1819693B1 (en) 2004-11-29 2009-08-26 Eli Lilly And Company Antithrombotic diamides
EP2077995B1 (en) * 2006-11-02 2012-02-08 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
EP2591354B1 (en) * 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006474A2 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827328B2 (ja) 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) * 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
US20130261130A1 (en) * 2010-11-01 2013-10-03 Shaheen Ahmed Neurotrypsin inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037643A1 (fr) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5417200A (en) * 1994-01-25 1995-05-23 Wasielewski; John J. Lantern cooker
ES2193202T3 (es) 1994-12-02 2003-11-01 Yamanouchi Pharma Co Ltd Nuevo derivado de amidinonaftilo o sal de este.
JP2002512633A (ja) 1997-06-26 2002-04-23 イーライ・リリー・アンド・カンパニー 抗血栓剤
AU8269398A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
CA2294126A1 (en) 1997-06-26 1999-01-07 Douglas Wade Beight Antithrombotic agents
US6372759B1 (en) 1997-06-26 2002-04-16 Eli Lilly And Company Antithrombotic agents
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
JP3811006B2 (ja) 1997-12-19 2006-08-16 シエーリング アクチエンゲゼルシャフト 抗凝血物質類としてのオルト−アントラニルアミド誘導体類
US6610704B1 (en) 1998-12-23 2003-08-26 Eli Lilly And Company Antithrombotic amides
ES2226485T3 (es) 1998-12-23 2005-03-16 Eli Lilly And Company Amidas aromaticas.
CA2358095A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Heteroroaromatic amides as inhibitor of factor xa
JP4390024B2 (ja) * 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
CN1390206A (zh) 1999-09-17 2003-01-08 千嬉药品公司 因子Xa的抑制剂
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
DE60130771T2 (de) * 2000-07-27 2008-07-17 Eli Lilly And Co., Indianapolis Substituierte heterocyclische amide
EP1379506A2 (en) * 2000-11-28 2004-01-14 Eli Lilly And Company Substituted carboxamides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037643A1 (fr) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives heterocycliques a fusion benzenique ou sels de ceux-ci

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160878B2 (en) 2000-07-27 2007-01-09 Eli Lilly And Company Substituted heterocyclic amides
WO2002064567A2 (en) * 2000-11-28 2002-08-22 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
WO2002064567A3 (en) * 2000-11-28 2003-11-06 Lilly Co Eli Substituted carboxamides as inhibitors of factor xa
US7163938B2 (en) 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
US7390908B2 (en) 2001-08-17 2008-06-24 Astrazeneca Ab Compounds effecting glucokinase
US7449457B2 (en) 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
WO2003050088A1 (en) * 2001-12-07 2003-06-19 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
US8247562B2 (en) 2002-04-05 2012-08-21 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
WO2003087057A1 (en) * 2002-04-05 2003-10-23 Astrazeneca Ab Benzamide derivatives useful as histone deacetylase inhibitors
JP2006527708A (ja) * 2003-06-18 2006-12-07 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 血栓症の治療のための凝固因子ＸａおよびＶＩＩａの阻害剤としての１−［（４−エチニルフェニル）］−２−［（フェニル）］−ピロリジン−１，２−ジカルボキサミド誘導体
US8227506B2 (en) 2005-02-02 2012-07-24 Ajinomoto., Inc. Benzamidine compound
US8207202B2 (en) 2005-10-19 2012-06-26 Astrazeneca Ab Benzamide compounds useful as histone deacetylase inhibitors
US8022208B2 (en) 2005-11-08 2011-09-20 Astellas Pharma Inc. Benzene derivative or salt thereof
JPWO2007055183A1 (ja) * 2005-11-08 2009-04-30 アステラス製薬株式会社 ベンゼン誘導体又はその塩
WO2007055183A1 (ja) * 2005-11-08 2007-05-18 Astellas Pharma Inc. ベンゼン誘導体又はその塩
JP5045442B2 (ja) * 2005-11-08 2012-10-10 アステラス製薬株式会社 ベンゼン誘導体又はその塩
WO2008123017A1 (ja) * 2007-03-09 2008-10-16 Daiichi Sankyo Company, Limited 新規なジアミド誘導体
WO2010005087A1 (ja) 2008-07-11 2010-01-14 味の素株式会社 アミジン誘導体
WO2010038689A1 (ja) * 2008-09-30 2010-04-08 アステラス製薬株式会社 経口投与用医薬組成物
JP4582263B2 (ja) * 2008-09-30 2010-11-17 アステラス製薬株式会社 経口投与用医薬組成物
CN102170885A (zh) * 2008-09-30 2011-08-31 安斯泰来制药株式会社 口服用药物组合物
JPWO2010038689A1 (ja) * 2008-09-30 2012-03-01 アステラス製薬株式会社 経口投与用医薬組成物
WO2013161871A1 (ja) * 2012-04-25 2013-10-31 興和株式会社 Ｔｌｒ阻害作用を有するチオフェン誘導体

Also Published As

Publication number Publication date
EP1273575B1 (en) 2004-05-19
TW575569B (en) 2004-02-11
DK1273575T3 (da) 2004-09-13
ATE340166T1 (de) 2006-10-15
DE60123294D1 (de) 2006-11-02
ATE267178T1 (de) 2004-06-15
EP1273575A1 (en) 2003-01-08
KR100739359B1 (ko) 2007-07-18
RU2257381C2 (ru) 2005-07-27
EP1415990B1 (en) 2006-09-20
PL207651B1 (pl) 2011-01-31
CN1319594A (zh) 2001-10-31
KR20010095174A (ko) 2001-11-03
HU0101333D0 (en) 2001-06-28
EP1415990A1 (en) 2004-05-06
DE60103390D1 (de) 2004-06-24
HUP0101333A3 (en) 2002-12-28
BR0101264A (pt) 2001-11-06
AR027985A1 (es) 2003-04-23
CA2395846C (en) 2009-08-11
ES2271464T3 (es) 2007-04-16
AU776053B2 (en) 2004-08-26
CA2395846A1 (en) 2001-10-11
PT1273575E (pt) 2004-09-30
HUP0101333A2 (hu) 2002-02-28
PL346731A1 (en) 2001-10-08
DE60123294T2 (de) 2007-04-05
JP3788349B2 (ja) 2006-06-21
TR200401955T4 (tr) 2004-09-21
US20030195193A1 (en) 2003-10-16
US20040068109A1 (en) 2004-04-08
ES2217129T3 (es) 2004-11-01
DE60103390T2 (de) 2005-06-16
CN1226292C (zh) 2005-11-09
US7307074B2 (en) 2007-12-11
EP1273575A4 (en) 2003-01-08
AU2982701A (en) 2001-10-04
US6642224B1 (en) 2003-11-04
USRE43481E1 (en) 2012-06-19
MXPA01003279A (es) 2004-07-30
AU2001244634A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
WO2001074791A1 (fr) Derives de diazepane ou sels desdits composes
FI950309A0 (fi) Proliiniamidijohdannaisia
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
JP2002053555A5 (ja)
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
NO20032261D0 (no) Medisinske preparater
EP1086946A4 (en) BENZAMIDINE DERIVATIVE
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
WO2002064552A8 (en) 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
WO2002036118A3 (en) Heterocyclic derivatives useful as pharmaceutical agents
WO2001068063A3 (en) Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
CA2320627A1 (en) Medicament for treatment of diastolic dysfunction
NO20043286L (no) Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
ATE403644T1 (de) Amidinophenylbrenztraubensäure-derivat
DE60008584D1 (de) Benzamidin-derivate
DK478989A (da) 1,4-dihydropyridinderivat, fremgangsmaade til dets fremstilling og farmaceutiske midler indeholdende det
EP1466909A4 (en) HALOGENBENZYLAMINOPROPIONSÄUREDERIVATE
TH22223B (th) " การรักษาโรคการรวมกันสำหรับการติดเชื้อ hiv"
TH88724A (th) การรักษา
TH42244A (ja)
TH45760B (th) สารละลายพรูคาโลไพรด์สำหรับการให้ทางปาก
TH54175A (th) (2s)-2-(แอดาแมนแทน-1-อิลเมธอกซิคาร์บอนิลอะมิโน)-3-(4-(2-(1,4,5,6-เททระไฮโดรพิริมิดิน-2-อิลคาร์บามออิล)เอธิล)เบนโซอิลอะมิโน)โพรพิออนิค แอซิด ไอโซโพรพิลเอสเทอร์, การเตรียมสารนั้นและการใช้สารนั้น

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 572486

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2395846

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001917634

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10148544

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001917634

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001917634

Country of ref document: EP